Lycia Therapeutics grants Fischer 20,000 options

The awards have separate vesting schedules: one vests 1/48 monthly over four years, and the other vests in full on October 22, 2027, subject to continued service.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. director Laurent Fischer received two stock-option awards: 13,307 options on August 11, 2026, with a $3.70 exercise price, and 20,000 options on October 22, 2026, with an $18 exercise price. The 13,307-option award vests 1/48 monthly over four years, with the first tranche vested on September 6, 2026, subject to continued service on each vesting date. The 20,000-option award vests in full on October 22, 2027, subject to continued service on that date.

Insider Trade Summary

Grant/Award: 33,307 shares

Grant/Award 2 txns

Insider Fischer Laurent

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F3	20,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1, F2	13,307	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 33,307 contracts (Direct)

Footnotes (3)

1. F1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
2. F2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. F3. The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Key Figures

Options awarded: 13,307 options Exercise price: $3.70 per share Option expiration: August 10, 2036 +5 more

8 metrics

Options awarded 13,307 options Awarded August 11, 2026

Exercise price $3.70 per share 13,307-option award

Option expiration August 10, 2036 13,307-option award

Vesting schedule 1/48 monthly over four years 13,307-option award; first tranche vested September 6, 2026

Options awarded 20,000 options Awarded October 22, 2026

Exercise price $18 per share 20,000-option award

Option expiration October 21, 2036 20,000-option award

Vesting 100% of the award Vests October 22, 2027, subject to service on that date

Key Terms

Stock Option (Right to Buy), vest, Rule 16a-2(a), Section 12 of the Exchange Act, +1 more

5 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest technical

"The options vest as to 1/48 of the total award monthly over four years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Rule 16a-2(a) regulatory

"reported herein pursuant to Rule 16a-2(a)"

Section 12 of the Exchange Act regulatory

"registration of a class of equity securities under Section 12 of the Exchange Act"

initial public offering financial

"in connection with the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did LYCA director Laurent Fischer receive?

Laurent Fischer received 13,307 options on August 11, 2026, and 20,000 options on October 22, 2026. Their exercise prices were $3.70 and $18 per share, respectively.

When do Laurent Fischer's LYCA options expire?

The 13,307-option award expires August 10, 2036, and the 20,000-option award expires October 21, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:21 PM EDT Accepted by SEC EDGAR 10/26/2026 - 07:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fischer Laurent

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7	08/11/2026(1)		A		13,307		(2)	08/10/2036	Common Stock	13,307	$0	13,307	D
Stock Option (Right to Buy)	$18	10/22/2026		A		20,000		(3)	10/21/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)